Daily Archives: March 31, 2021

VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that it has been added to the Horizons Psychedelic Stock Index ETF (PSYK) in its first quarterly rebalance of holdings.

PSYK (PSYK: NEO) is the world's first ETF (Exchange Traded Fund) offering direct exposure to North American publicly listed securities that have significant business activities in, or significant exposure to, the psychedelics industry. The underlying index is the North American Psychedelic Stock Index, which is a proprietary index owned and operated by Horizons ETFs, and Solactive AG is the independent calculation agent for the index.

On February 1st, 2021, Algernon announced that it had established a clinical research program for the treatment of stroke focused on AP-188 (N,N-Dimethyltryptamine or DMT), a known psychedelic compound, said Christopher J. Moreau CEO of Algernon Pharmaceuticals. Being added to the PSYK is a reflection of the important work Algernon has undertaken with its DMT stroke research program and will help bring a further level of awareness to the Company among a wide range of investors.

About Horizons Psychedelic ETF and the North American Psychedelic Index

The Horizons Psychedelic ETF is the world's first exchange traded fund offering direct exposure to North American publicly listed securities that have significant business activities in, or significant exposure to, the psychedelics industry. Horizons ETFs Management (Canada) Inc. which manages the fund, is a global ETF provider with ETF solutions available to investors across the globe. Horizons ETFs have over $17.5 billion of assets under management and 88 ETFs listed on major Canadian stock exchanges.

The underlying index for the Horizons Psychedelic ETF is the North American Psychedelic Stock Index, which is a proprietary index owned and operated by Horizons ETFs, with Solactive AG being the independent calculation agent for the index. The Index, which rebalances each calendar quarter, has been designed to provide a measure of the performance of North American publicly listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry.

Story continues

DMT Background

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesised in a laboratory.

At higher doses, DMT has a rapid onset, intense psychedelic effects, and a relatively short duration of action with an estimated half-life of less than fifteen minutes. Like other hallucinogens in the tryptamine family, DMT binds to serotonin receptors to produce euphoria and psychedelic effects. Because the effects of DMT do not last very long, it has been referred to in some circles as the businessmans trip.

Named the Spirit Molecule by Dr. Rick Strassman, an American clinical associate professor of psychiatry and DMT research pioneer, DMT has been shown to induce neuroplasticity in a number of key preclinical studies. DMT is believed to activate pathways involved with forming neuron connections and has been shown in studies to increase the number of dendritic spines on cortical neurons. Dendritic spines form synapses (connections) with other neurons and are a major site of molecular activity in the brain.

While Dr. Strassmans Phase 1 bolus intravenous human study identified the sub-hallucinogenic dose of DMT in humans, another preclinical animal study demonstrated this same dose level still retains the neuroplastic effect seen in higher hallucinogenic doses.

Algernon will be investigating an intravenous sub-psychedelic dose of DMT as a potential treatment for Stroke in its research and clinical studies.

Algernon has filed new provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and constraint-induced movement therapy (CIMT).

About Algernon Pharmaceuticals Inc.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

CONTACT INFORMATION

Christopher J. MoreauCEOAlgernon Pharmaceuticals Inc.604.398.4175 ext 701

info@algernonpharmaceuticals.cominvestors@algernonpharmaceuticals.comwww.algernonpharmaceuticals.com.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as will, may, should, anticipate, expects and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Companys expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Read more here:

Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF - Yahoo Finance

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce that Robert Tessarolo, President & Chief Executive Officer, will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference that will be held virtually from May 4-6. He will be speaking on the use of psychedelics in treating obesity and eating disorders.

Figure 1: NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference

To view an enhanced version of Figure 1, please visit:https://orders.newsfilecorp.com/files/7646/78904_neon2.jpg

The conference will unite the top business and academic leaders including Frederick Barrett, Ph.D., Assistant Professor of Psychiatry & Behavioral Sciences at Johns Hopkins School of Medicine, to discuss, analyze, and share intelligence on regulatory changes and other challenges on psychedelic research for treatment of a myriad of serious chronic medical conditions.

"The Psychedelic, Therapeutics, and Drug Development Conference is an excellent opportunity for NeonMind to share our vision and progress with other industry leaders and key stakeholders," said Rob Tessarolo. "I also look forward to listening to the many great experts and innovators who will discuss a number of regulatory and policy changes that will help unlock the full health potential of this emerging field."

NeonMind is currently advancing two (2) psilocybin-based drug development programs aimed at treating obesity. Psychedelic therapy has the potential to institute long term positive behaviours that may aid in weight loss and its maintenance, and psilocybin in low doses may help control appetite and satiety.

"There is a clear need for new treatments, new solutions, new approaches for the obesity epidemic and psychedelics are well positioned to offer new therapeutic breakthroughs," said Rob Tessarolo. "NeonMind will continue to advance our important research and be a leader in commercialization following regulatory approval."

Story continues

About NeonMind Biosciences Inc.

NeonMind is engaged in research and development of products to optimize human health and performance. NeonMind has two divisions, a pharmaceutical division engaged in drug development of psychedelic compounds, and a consumer products division with a focus on mushroom infused products. NeonMind's consumer division currently sells 4 NeonMind branded coffee products in Canada through NeonMind's direct to consumer e-commerce platform, and it has plans to launch products in Canada as natural health products once Health Canada approves its recent applications. NeonMind also plans to launch dietary supplements in the United States this spring.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind's first drug candidate aims to use synthetic psilocybin to enhance a patient's ability to adopt behaviours that cause weight loss and maintain that loss through psychedelic-assisted cognitive therapy. The second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.

NeonMind's first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is involved in the hallucinogenic effect of psychedelics, and the second drug candidate employs low-dose psilocybin as an agonist to the 5-HT2C receptor, which controls appetite.

For more information on NeonMind, go to http://www.NeonMindBiosciences.com.

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.rob@neonmind.com Tel: 416-750-3101

Investor Relations:Edge Communicationsinvest@neonmind.com Tel: 1-866-318-6874

Renmark Financial Communications Inc. Melanie Barbeaumbarbeau@renmarkfinancial.com Tel: 416-644-2020 or 212-812-7680

Media Inquiries:Exvera Communications Inc.brittany@exvera.com

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind's future performance. The use of any of the words "could", "expect", "believe", "will", "projected","estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/78904

Original post:

NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference - Yahoo Finance

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor LiveChats on social media streams. Over 160,000 investors have participated in Wall Street Reporters livestream events in the past 30 days.

Interactive Games Technologies (CSE: BETS) (OTC: BLITF), CEO Chris Neville: "Building Next Billion Dollar Global Betting Giant"

In a recent interview at Wall Street Reporters NEXT SUPER STOCK livestream, Interactive Games Technologies (OTC: BLITF) (CSE: BETS) CEO Chris Neville, shares his companys ambitious global strategy, with a unique focus on India. As a pioneer of online gaming with almost 20 year's experience, Neville sees a strong parallel between the poker boom of the early 2000s and the Indian market today.

Watch (CSE: BETS) (OTC: BLITF) NEXT SUPER STOCK Video: http://bit.ly/2Zuubon

India is one of the fastest growing online gaming markets in the world. With a growing population, especially the middle class, a burgeoning economy, the fastest internet adoption in the world, and with 65% of the population under the age of 35, India is the perfect storm for skill based online gaming.

Interactive Games Technologies (OTC: BLITF) (CSE: BETS) sees India as the perfect launchpad for its global betting business, with relatively low customer acquisition costs, less competition, and blue sky upside potential. By partnering with Indian social influencers such Bollywood celebrities and cricket stars, BLITF reaches their 150 million followers in India. BLITF is also expanding into new untapped global gaming markets such Canada which is about to legalize sports betting.

March 23 - BLITF reports that launch of its recently acquired skill-based fantasy gaming product, BLITZPOOLS, is exceeding expectations. BLITZPOOLS is already over 150,000 new registrations and expects to close the month with over 250,000 new players. It is clear the industry leading product and brand positioning is resonating with the Indian fantasy gaming audience, and is now one of Indias fastest-growing skill-based fantasy sports platforms.

Story continues

March 16 - BLITF announces plans to enter US gaming market. BLITF management is in talks with US land-based casino to partner in building and managing a digital gambling platform and offering. Morgan Stanley estimates that the U.S. online gambling market (sports betting and iGaming) will soon top $20 billion Gross Gaming Revenue per year. The lack of permissive online gambling regulations until recently in the U.S. means that online gambling experience is limited in the U.S. market. Online gambling has, however, been permitted in other countries and regions for over two decades. BLITF has assembled a team of online gambling executives, with over 100 years online gambling experience, and believes can provide land-based operators with the knowledge, experience and expertise to capitalise on the growing US online gambling market. BLITF CEO, Chris Neville said: The Company is hugely excited by this opportunity in the burgeoning U.S. online gambling market. We have a great team and a great partner to add significant value to future potential partners in this space.

March 8 - BLITF announces signing of rising cricket stars Ishan Kishan, Rahul Chahar, Shreyas Gopal and Wriddhiman Saha to be the face of the brand. Attracting their ever-growing and large fan base to the app, the cricketer quartet will be an integral part of the 360-degree digital and offline campaign activation of BLITZPOOLS. In addition to these cricket stars and as part of the new brand launch, BLITZPOOLS has engaged celebrities and influencers alike with a total follower count in excess of 215 million, the identities of which will be revealed at time of post and in a future release.

Watch (CSE: BETS) (OTC: BLITF) NEXT SUPER STOCK Video: http://bit.ly/2Zuubon

Hapbee Technologies (OTC: HAPBF) CEO Scott Donnell: Tech That Lets You Choose How you Feel = Billion Dollar Market OpportunityOne of the most unique companies to present at Wall Street Reporters NEXT SUPER STOCK livestream events in recent years, is Hapbee Technologies (OTC: HAPBF) which markets wearable tech that lets you choose feelings on demand. The patented technology uses low-power electromagnetic signals designed to produce sensations such as Happy, Alert, Focus, Relax, Calm and Sleepy. HAPBF is developing new feeling signals regularly which are available on a subscription basis through its mobile app.

In his interview with Wall Street Reporter, Hapbee CEO Scott Donnell explains how Hapbees technology platform addresses untapped multi-billion dollar market opportunities which include mental health, sleep, and fitness, among other aspects of our daily lives which are impacted by feelings. Scott also shares HAPBFs unique D2C e-commerce strategy which is based on proven systems of todays most successful billion-dollar D2C fitness, health and lifestyle brands. Hapbee is rapidly being embraced by influencers in fitness/wellness, biohackers, and high-performance executives who want to perform and feel their best. HAPBF unique technology positions it at the forefront of the fast growing $32 billion wearable tech market.

Watch Hapbee Technologies (OTC: HAPBF) NEXT SUPER STOCK Video: http://bit.ly/3vh6Ncx

ESE Entertainment (TSX.V: ESE) (OTC: ENTEF) CEO Konrad Wasiela: E-Sports M&A Pipeline With Over $100 million Annual Revenues

ESE Entertainment (TSX.V: ESE) (OTC: ENTEF) CEO Konrad Wasiela, a featured presenter at Wall Street Reporters NEXT SUPER STOCK investors livestream conference, recently updated investors on his goal of building ESE into a billions dollar global enterprise. Wasiela shared that ESE now has a growing M&A pipeline with over $100 million annual revenues and expected to close a significant number of these potential transactions in the coming months. ESEs stated goal is to build a global E-Sports business with a valuation of $1 Billion+.

Watch ESE (OTC: ENTEF) Next Super Stock livestream video: https://bit.ly/3qq59mb

In his interview with Wall Street Reporter, ESE CEO Konrad Wasiela, says the company is now ready to scale - expanding its global footprint, with new partnerships with global brands like Porsche, driving revenue growth with aggressive focus on top line sales and margin expansion, and M&A opportunities. ESE is now rapidly expanding, with multiple revenue streams including, E-Sports infrastructure software powering global tournaments, exclusive digital media distribution, broadcast rights, and owning world-class leagues and teams, including its K1CK global E-Sports franchise.

March 17 - ENTEF announces launch of Virtual Pitstop, a new business unit dedicated to simulation racing (sim racing). Virtual Pitstop will provide technology for video game developers, racing fans, and gamers to engage in motorsport related esports across the globe. ENTEF CEO Konrad Wasiela, commented, We are excited to announce the expansion of our digital Motorsport business with the launch of the Virtual Pitstop brand. Our past successful partnerships and business collaborations with Porsche, Kia, and Orlen are just the beginning. We see a significant opportunity to implement fast growing technology and monetization via AR/VR, NFTs, skins, and more.

Watch ESE (OTC: ENTEF) Next Super Stock livestream video: https://bit.ly/3qq59mb

Delic Holding (CSE: DELC) (OTC: DELCF) CEO Matt Stang: Psychedelics For Mental Health Is Major Growth Trend

In a recent interview at Wall Street Reporters Investors Discovery Day livestream, Delic Holdings (OTC: DELCF) CEO Matt Stang shared his unique strategy for capitalizing on what is expected to be the next massive new market opportunity: psychedelics. As the former publisher of High Times Magazine over 14 years, Matt Stang paved the way for cannabis legalization, and along the way, developed a network of industry pioneers who are now active in the psychedelics space. In his interview, Stang explains DELCFs unique psychedelics ecosystem business model - which offers synergies, and leverage - and generates revenues across the entire psychedelics value chain.

DELCFs ecosystem spans across an online media platform which provides consumers information and reviews, on psychedelics - an expanding chain of ketamine treatment clinics - to a licensed research lab developing innovative psychedelics product formulations - to clinical research data for biotech & pharma for developing new psychedelic compounds. DELCF intends to expand this ecosystem further, through M&A, leveraging Matt Stangs 14 years of experience and wide industry contacts across the industry.

Watch DELCF NEXT SUPER STOCK video: http://bit.ly/3uK4L4y

March 5 - DELCF announces acquisition of the Homestead brand and intellectual property. Homestead is a legacy counterculture distributor of psychedelic media and creator of one of the first self-contained mushroom grow kits. Matt Stang, Founder and CEO of DELCF commented, "The acquisition of Homestead is an exciting one for us at DELIC. It shows how we are increasing accessibility to this nascent industry within regulated jurisdictions. Homestead not only sold tens of thousands of mushroom kits globally but also was one of the earliest distributors for High Times and many other counter culture publications. We look forward to growing together and increasing shareholder value with what we accomplish."

February 25 - DELCF announces acquisition of Complex Biotech Discovery Ventures, a licensed psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Glenn Sammis, CBDV supports the psychedelic industry with high precision chemical analytics and metabolomic identification.

Watch DELCF NEXT SUPER STOCK video: http://bit.ly/3uK4L4y

WALL STREET REPORTER

Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. http://www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K

About Wall Street Reporters Next Super Stock conference:

Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/

CONTACT:

WALL STREET REPORTER

(212) 871-2057 ext 7

http://www.WallStreetReporter.com

Here is the original post:

NEXT SUPER STOCKS On The Move: E-Sports, Psychedelics, iGaming, and FeelTech - CEOs of BLITF, ENTEF, HAPBF and DELCF, Positioning for Explosive...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer, and Aaron Bartlone will serve as Chief Operating Officer of Cybin US Holdings Inc. The Company also announced that co-founder and former Chief Operating Officer, Paul Glavine will assume the role of Chief Growth Officer of Cybin Inc., and co-founder and former SVP, Business Development, John Kanakis will assume the role of Chief Business Officer.

We are committed to building our presence both in the United States and in Europe to advance our mission of improving mental healthcare through therapeutic development programs and innovative drug delivery systems. These appointments will serve to strengthen our development and clinical operations globally and solidify Cybins position within the industry. Alex and Aaron bring deep clinical, commercial and regulatory expertise that will serve to broaden our management and scientific leadership teams. We look forward to their contributions as we pursue increased visibility across these additional markets, stated Doug Drysdale, Chief Executive Officer.

Paul and Johns extensive entrepreneurial experience was instrumental in shaping the initial formation of Cybin and the companys subsequent emergence as a leader within the psychedelics space. Their deep commitment to Cybins mission will continue as they assume these new roles and will allow them to further accelerate business development and investor awareness initiatives. We believe these appointments are an important step in taking Cybin to the next level, concluded Drysdale.

Mr. Bartlone is an accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, including quality assurance, regulatory affairs, product development, compliance, and commercial operations. Prior to joining Cybin, Mr. Bartlone was President & Managing Director at AB Dynamix LLC, where he was responsible for developing customized and innovative quality management systems, regulatory strategies, and supply chains for developing pharmaceutical, biotechnology, and medical device companies. Previously, Mr. Bartlone held positions of increasing responsibility at UCB Inc., a global pharmaceutical company, including Commercial President and Chief Quality, Patient Safety, Health Safety & Environment & Risk Officer. Mr. Bartlone has developed global teams of over 1,000 colleagues in 50 countries and has successfully driven over 25 small and large molecular therapies and drug-device combination products to the global marketplace. Mr. Bartlone has also held various director-level research, quality, regulatory, and managerial positions at Eli Lilly. Mr. Bartlone has a Bachelor of Science in Chemistry from Youngstown State University and a Master of Science in Analytical Chemistry from the University of Notre Dame.

Dr. Alexander Belser is a well-known leader in the field of psychedelic research, having served as an investigator on clinical trials of psilocybin and MDMA to treat depression, anxiety, substance use, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and end-of-life distress at New York University and Yale University. Dr. Belser previously served as Chief Clinical Officer at Adelia Therapeutics, where he directed the clinical program investigating tryptamines and phenethylamines for a variety of treatment indications. Dr. Belser is the founding President of Nautilus Sanctuary, the first non-profit center for psychedelic medicine in the eastern United States. Dr. Belser has taught widely on the topic of psychedelic medicine, having authored a dozen peer-reviewed publications and given over fifty lectures, presentations, and Grand Rounds on psychedelic topics. As a Clinical Research Fellow and Co-Investigator at Yale University, Dr. Belser investigated psychedelic treatments for major depression and for OCD. Dr. Belser has worked as a therapist on studies of MDMA-assisted psychotherapy for the treatment of severe PTSD. Dr. Belser trained at Bellevue Hospital, Mount Sinai Beth Israel Hospital, and New York Psychiatric Institute at Columbia University. Dr. Belser has also received extensive training in psychedelic psychotherapy from recognized senior teachers. Dr. Belser has Bachelor of Arts degrees in English and Government from Georgetown University, a Master of Arts in Philosophy from Cambridge University, and a PhD in Counseling Psychology from New York University.

About Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as may, should, could, intend, estimate, plan, anticipate, expect, believe or continue, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the development of the Companys operations and presence in the United States and Europe and the Companys advancement of therapeutic development programs and innovative drug delivery systems. There are numerous risks and uncertainties that could cause actual results and Cybins plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

See the rest here:

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe - Business Wire